Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.60 |
| ▸ | HTR7 | P34969 | 4/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | HTR2B | P41595 | 4/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1E | P28566 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2076444 | 0.89 | HTR7 (0.63) | HTR2AHTR7HTR1AABL1HTR2C | |
| SCHEMBL2074048 | 0.82 | HTR2A (0.54) | HTR2AHTR7HTR1AABL1HTR2C | |
| SCHEMBL2074492 | 0.81 | HTR2A (0.52) | HTR2AHTR7HTR1AHTR2CHTR2B | |
| SCHEMBL2076810 | 0.78 | HTR7 (0.88) | HTR2AHTR7HTR1AHTR2CHTR2B | |
| SCHEMBL2076474 | 0.78 | HTR2A (0.71) | HTR2AHTR7HTR1AHTR2CHTR2B | |
| SCHEMBL2075834 | 0.78 | HTR7 (0.60) | HTR2AHTR7HTR1AABL1HTR2C | |
| SCHEMBL2077143 | 0.76 | HTR2A (0.68) | HTR2AHTR7HTR1AHTR2CHTR2B | |
| SCHEMBL14712485 | 0.76 | HTR7 (0.68) | HTR2AHTR7HTR1AHTR2CHTR2B | |
| SCHEMBL2073841 | 0.76 | HTR7 (0.68) | HTR2AHTR7HTR1AHTR2CHTR2B | |
| Jnj-18038683 Free Base SCHEMBL2076477 | 0.75 | HTR7 (1.00) | HTR2AHTR7HTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | BONAVENTURE PASCAL | 2009-11-05 | — | — | US | claimed |
| EP-1668014-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-01-14 | — | — | EP | claimed |
| EP-2052251-B1 | COMBINATION 5-HT7 RECEPTOR ANTAGONIST AND SEROTONIN REUPTAKE INHIBITOR THERAPY | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-07 | — | — | EP | disclosed |
| US-8883808-B2 | Combination of 5-HT7 receptor antagonist and serotonin reuptake inhibitor therapy | JANSSEN PHARMACEUTICA N.V. (BE) | 2014-11-11 | — | — | US | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | BONAVENTURE PASCAL | 2009-11-05 | — | — | US | disclosed |
| EP-1944306-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | HTR2A 9/4885HTR7 17/4885HTR1A 8/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR2A 9/4885HTR7 17/4885HTR1A 8/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | HTR2A 9/4885HTR7 17/4885HTR1A 8/4885 |
| US-20090275563-A1 | Combination of 5-HT7 Receptor Antagonist and Serotonin Reuptake Inhibitor Therapy | HTR7, HTR1A, HTR6 | HTR2A 10/4885HTR7 1/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.